Accelerate the sinking of medical resources and improve the global access to high quality medical care
In recent years, there has been a growing demand for medical resources worldwide. In some low-resource areas, high-quality medical resources are difficult to cover all the needs. After the COVID-19 outbreak, real-time diagnosis quickly entered the public eye. Point-of-care testing diagnosis is a diagnostic method in which results can be obtained at site and in a short time. Its emergence can help to improve the utilization efficiency of medical resources, and better meet the needs of the public, and well solve the problem of disease screening in resource-poor areas.
As a POCT enterprise integrating R&D, production, and sales of instruments and reagents, Wizbiotech has more than 120 certified reagents exported to Germany, Italy, Spain, Finland, Netherlands, Indonesia, Malaysia, Peru, and other countries. Wizbiotech has developed strategic cooperation with Abbott Laboratories, a leading company in the field of in vitro diagnostics. As the partner institution of Abbott Rapid Diagnostics in China, Wizbiotech is also entering into a series of international collaborations to jointly improve the global health and promote human health development through cooperation, support, and complementary.
If interested, please get in touch with Wizbiotech sales to learn more about the company's products.
